EMA Authorised: Xofigo (radium (223Ra) dichloride) — Bayer AG

View source ↗

Summary

EMA authorises Xofigo (radium-223 dichloride) for therapeutic use in prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Bayer AG. Decision date: 23/07/2026